GL Rapha and Viropro, Inc. Announce Signing of Memorandum of Understanding

15:09 EDT 10 May 2013 | BioPortfolio


May 10th 2013 SEOUL, KOREA & BUFFALO, NY, USA - LRapha and Viropro, Inc. announced that the two companies entered into a Memorandum of Understanding that sets the groundwork for close collaboration for matters related to mutual business development over the next two years.

More particularly, GLRapha and Viropro agreed to pursue business development in the biopharmaceutical market in the Malaysia and Indochina region and form joint venture(s) where appropriate to enhance price competitiveness and promote successful production and marketing of biopharmaceutical products.  This may include license-producing agreements, management assistance agreements, technical assistance and technology transfer agreements, distribution agreements and/or reciprocal referral agreements.

The Memorandum of Understanding was officially signed on April 22, 2013 at the BIO 2013 Conference in Chicago, IL.

About Viropro Inc.
Viropro specializes in the development and manufacturing of biopharmaceutical drugs and is focused on the development and commercialization of its proprietary Rituximab and insulin biosimilars as well as mAbs manufacturing at its Penang, Malaysia facility.  The company conducts operations through its subsidiaries, Viropro International Inc. (Montreal, Canada), Biologics Process Development (Poway, CA) and Alpha Biologics (Penang, Malaysia).

Viropro offers it process development and GMP manufacturing services to a wide array of pharmaceutical and biotechnology companies. It has an international client base, from small and medium sized companies that are seeking assistance in getting their new drug into clinical trials to large pharma groups interested in biosimilars/biobetters or diversifying into novel biotech drugs.  Through its proprietary technologies and flexible business model, Viropro can offer cost-effective and timely solutions to the biopharma industry from drug concept through to product manufacturing.

For more detailed information about the company, contact Cynthia Tsai,

About GL Rapha
GLRapha is a globally-focused Korean company focused on the pharmaceutical industry to improve human welfare.  GLRapha has an R&D center and production facilities to fulfill its mandate to lead the creation of a globally competitive pharmaceutical pipeline with technologically advanced factories to produce high-quality biopharmaceuticals focused on the development of biopharmaceuticals.  GLRapha is aiming at the global localization for maximizing mutually beneficial collaborations and business ventures with a strong global network.
For more detailed information about the company, contact SooWon. Jang, Project Manager,


More From BioPortfolio on "GL Rapha and Viropro, Inc. Announce Signing of Memorandum of Understanding "

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...